<?xml version="1.0" encoding="UTF-8"?>
<ref id="tca13424-bib-0018">
 <label>18</label>
 <mixed-citation publication-type="journal" id="tca13424-cit-0018">
  <string-name>
   <surname>Alsaab</surname>
   <given-names>HO</given-names>
  </string-name>, 
  <string-name>
   <surname>Sau</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Alzhrani</surname>
   <given-names>R</given-names>
  </string-name>
  <italic>et al</italic>
  <article-title>PD‐1 and PD‐L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome</article-title>. 
  <source xml:lang="en">Front Pharmacol</source>
  <year>2017</year>; 
  <volume>8</volume>: 
  <fpage>561</fpage>.
  <pub-id pub-id-type="pmid">28878676</pub-id>
 </mixed-citation>
</ref>
